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Previously, we generated human monoclonal antibodies using peripheral blood mononuclear cells from an asymptomatic
human immunodeficiency virus type 1 (HIV-1)-seropositive donor. One of these monoclonal antibodies (designated clone 3,
CL3) recognized 10 amino acids (GCSGKLICTT) within the immunodominant region (cluster I) of the transmembrane envelope
glycoprotein gp41 and neutralized infection of target cells with different laboratory isolates. Because the epitope recognized
by CL3 has two cysteine residues that could potentially produce a disulfide loop in gp41, we analyzed binding of our
monoclonal antibody to the cyclic and linear motif of the peptide sequence IWGCSGKLICTTAVP (residues 600–614). The CL3
antibody did not bind to the synthetic cyclic peptide but did recognize the linear form. Two polyclonal rabbit sera against both
the linear and cyclic peptides were then generated. Both antisera bound to viral glycoproteins gp41 and gp160, but neither
sera neutralized HIV-1 laboratory isolates. Using a set of alanine-substituted IWGCSGKLICTTAV peptides, we analyzed
binding of polyclonal antisera and CL3. The profile of binding of polyclonal antisera to these peptides was different from that
of CL3 to the same peptides. This suggests that CL3 recognized a unique neutralizable core epitope, which was not
immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits. © 2000
Academic Press
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TINTRODUCTION
Intensive investigation of the immunological re-
sponses against human lentiviruses has generated con-
siderable information regarding the relevant specific im-
mune responses (Cao et al., 1995; Clerici et al., 1993; Lu
et al., 1996; Pantaleo et al., 1995; Parry et al., 1994;
aynes, 1996). In the first 2 weeks after infection by
uman immunodeficiency virus (HIV), serum levels of
irus initially increase and then gradually decrease. The
eneration of high antibody titers and cytotoxic T-lym-
hocytes (CTL) against different viral proteins was re-
orted to occur during primary infection (Cao et al., 1995;
lerici et al., 1993; Parry et al., 1994; Gardner et al., 1994;
u et al., 1992; Haynes et al., 1996; Palker et al., 1989;
avaherian et al., 1989; Sarin et al., 1986). Anti-HIV-1
1 Monica Viveros and Chad Dickey contributed equally to this work
nd are listed as co-first authors.
2 To whom reprint requests should be addressed at Department of
Microbiology and Immunology, MDC 10, University of South Florida
College of Medicine, Tampa, FL 33612. Fax: (813) 974-4151. E-mail:
kugen@hsc.usf.edu; or Joseph Cotropia at Fax: (305) 832-0519, E-mail:
cotropia@fast.net.
135ntibodies involved in antibody-dependent cellular cyto-
oxicity (ADCC) of infected cells were also elicited (Ljung-
ren et al., 1989). High frequencies of anti-HIV-1 CD81
CTLs were detected in infected patients during the
asymptomatic stage (Hoffenbach et al., 1989). These
TLs, which were found in a majority of lymphoid organs
f infected patients, could lyse the infected cells, release
ifferent cytokines/chemokines (McMichael, 1998), and
ontrol the early replication of the virus. Furthermore, the
evel of specific CTLs has been reported to decrease
ith disease progression, linking CTL responses to a
ore benign clinical status (Guyader et al., 1987; Clerici
t al., 1992). This observation clearly suggests that anti-
iral CTLs can effectively control HIV-1 infection. Re-
ently, a direct correlation between anti-HIV-1 CTL activ-
ty and plasma viral RNA was demonstrated using anti-
en-peptide tetrameric complexes (McMichael, 1998;
gg et al., 1998). A vigorous anti-viral T-helper cell pro-
iferation in individuals who control HIV-1 replication
ithout anti-retroviral therapy was also demonstrated.
he CD41 T-helper cells produced both interferon-g andb-chemokines during in vitro stimulation. Thus, it was
shown that T-helper cells were required not only for
0042-6822/00 $35.00
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136 VIVEROS ET AL.generation of anti-HIV-1 CTLs and antibodies but also for
controlling HIV-1 infection and slowing the clinical pro-
gression to AIDS (Rosenberg et al., 1997).
Therefore, the immune system appears to control viral
infection initially (Ho et al., 1995) through the generation
of humoral and/or cellular immune responses, and these
early responses may explain the long period of asymp-
tomatic infection before disease development in humans
(Cao et al., 1995). This suggests that an effective HIV-1
vaccine should generate both cellular (i.e., Th and/or
CTL) and humoral (Ab) immune responses. However,
recent data indicate that although anti-HIV-1 antibodies
generated throughout the course of infection neutralize
homologous virus, they have little neutralizing activity
against other primary isolates (Montefiori et al., 1996). In
ddition, it was demonstrated that high titers of the
eutralizing anti-envelope antibodies persisted during
rimary infection (Pilgrim et al., 1997). This suggests that
he majority of antibodies generated in organisms with
atural infection are not sufficient to inhibit HIV-1 repli-
ation. These results also correlate with attempts to
enerate human anti-HIV-1 monoclonal antibodies with
road neutralizing capacities. Only a few hybridomas
hat produce such anti-gp41 (Cotropia et al., 1992, 1996;
Xu et al., 1991; Eaton et al., 1994; Muster et al., 1993;
Robinson et al., 1990a,b, 1991; Bugge et al., 1990) or
anti-gp120 (Thali et al., 1992, 1993; Burton et al., 1994; Ho
et al., 1991; Karwowska et al., 1992; Kang et al., 1993;
rkola et al., 1996) antibodies have been generated using
B cells of infected patients (Buchacher et al., 1994).
Several of these have been demonstrated to neutralize
laboratory adapted as well as clinical isolates. The gen-
eration of these hybridomas supports the hypothesis that
potential neutralizing antibodies can be elicited by vac-
cination, if appropriate viral antigens (epitopes) are cho-
sen for immunization (Burton, 1997).
In this report, we analyzed epitopes in the immuno-
dominant (cluster I) region of gp41 using our human MAb
CL3 and two polyclonal rabbit sera. We demonstrated
that CL3 recognized a unique normally nonimmunogenic
neutralizable epitope.
RESULTS
CL3 antibody recognizes a linear epitope on
oligomeric gp160
The CL3 MAb bound to monomeric gp160 and gp41
(Cotropia et al., 1996). Here we analyzed the binding of
his antibody to oligomeric envelope gp160. At a concen-
ration of 5 mg/ml, CL3 antibody bound not only to mo-
nomeric gp160 but also to oligomeric gp160. Importantly,
binding to the oligomeric HIV-1 glycoprotein was higher
than to that of the monomeric motif (Fig. 1). Therefore, the
CL3 MAb recognizes an epitope expressed not only onthe monomeric but also on the oligomeric envelope pro-
tein of HIV-1. Earlier the CL3 MAb had been epitope-
mapped to the ectodomain of gp41 (GCSGKLICTT resi-
dues 602–611) utilizing 10 overlapping pentadecapep-
tides (Cotropia et al., 1996). It was revealed that two
cysteines in this region might form a single intrachain
disulfide bond in gp41, producing a loop (Goudsmit et al.,
1990) that could be important for folding of gp41 during
the fusion of HIV-1 with target cells (Chan et al., 1998).
Therefore, for further characterization of the CL3 epitope,
we chemically synthesized a cyclic 15-mer peptide with
the sequence IWGCSGKLICTTAVP (residues 600–614)
that includes the original ectodomain recognized by the
CL3 MAb. This cyclic peptide and its linear conformation
[in the presence of 70 mM 2-b-mercaptoethanol (2ME)]
were used in an ELISA to demonstrate the affinity of CL3
for them (Fig. 2). We demonstrated that the CL3 MAb
bound to the peptide only in the presence of 2ME (linear
conformation). The level of binding to the cyclic peptide
(without 2ME) was equal to the level of binding of the
negative control. These results have been reinforced by
the binding of the CL3 MAb to a synthetic 14-amino-acid
linear peptide IWGASGKLICTTAV (data not shown) in
which the cysteine residue at 603 was substituted with
an alanine. Thus, we have demonstrated that the CL3
MAb binds to a linear neutralizable epitope within the
immunodominant region of gp41. This provided the ratio-
FIG. 1. Binding of CL3 to monomeric gp160/IIIB and oligomeric
gp160/LAV envelope glycoproteins. Human IgG1 is used as a negative
control. CL3 and human IgG1 were added at concentrations of 5 mg/ml.
ound antibodies were detected with HRP-conjugated polyvalent rabbit
nti-human Ig.nale for the generation of rabbit antisera against this
epitope.
tection
137AN HIV-1 NEUTRALIZABLE LINEAR EPITOPE IN gp41Binding of rabbit sera to cyclic and linear peptides
and HIV-1 glycoproteins
Rabbit antisera was generated against both linear and
cyclic peptides from the gp41 region of HIV-1 to further
analyze immunogenicity of the CL3 epitope. Antisera
generated against the cyclic peptide bound to only the
cyclic peptide in an ELISA, whereas anti-linear peptide
bound only to the linear peptide (Figs. 3A and 3B). Im-
portantly, both antisera bound to HIV-1 glycoproteins. In
fact, the binding to oligomeric gp160 was higher than to
that of monomeric gp41 (Fig. 4). These findings deter-
mined that there is potentially a difference in the immu-
nological capability of antibodies raised against a pep-
tide due to a single amino acid difference causing a
conformational change. Thus, it was next important to
further characterize the epitope of CL3 using a set of
single amino acid substitution peptides.
Demonstration of the fine epitope specific
for the CL3 MAb
Determination of the fine epitope could potentially
characterize the ability of the CL3 MAb to neutralize
HIV-1. Thus it was necessary to determine the core
amino acids involved in the reactivity of the CL3 MAb
against HIV-1 gp41. A set of peptides was generated
(Goudsmit et al., 1990) to more specifically map the
epitope of CL3. These peptides consisted of a sequential
FIG. 2. Binding of CL3 to parent peptide (IWGCSGKLICTTAVP, residu
and maintained through the addition of 70 mM 2ME. CL3 and HIgG
concentrations to wells coated with 750 ng of the parent peptide. De
anti-human Ig.single amino acid substitution, exchanging each amino
acid in GIWGCSGKLICTTAV (residues 599–613) peptidewith alanine (except that the original alanine, A, at posi-
tion 612 was substituted with lysine, K). The results
demonstrated that substitution of any single amino acid
had a significant influence on the binding capacity of CL3
to these peptides. Substitutions at amino acid positions
613, 606, 603, and 601 substantially decreased the bind-
ing capacity of the CL3 MAb. However, substitution of
three amino acids specifically at positions 607 (L), 608 (I),
and 609 (C) had a much more dramatic effect on the
interactions. These three residues were absolutely cru-
cial for the binding of CL3 to the appropriate peptides
(Fig. 5). Importantly we should mention that all of these
experiments have been performed in the presence of the
reducing agent 2ME. This explains why the CL3 MAb
binds to the parent peptide. In this way, all of our pep-
tides, parental and experimentally modified, were par-
tially maintained in their linear form and could not form
intermolecular disulfide linkages.
Using the same approach, we analyzed binding of the
rabbit polyclonal anti-linear (Fig. 6A) and anti-cyclic (Fig.
6B) sera to the same set of alanine-substituted peptides.
As we expected, anti-linear sera bound to the parental
peptide whereas any single amino acid substitution
greatly decreased the binding of this antisera to any of
the peptides. Concerning the anti-cyclic sera, we found
that it binds to the cyclic peptide very well as demon-
strated above (Fig. 3A). When we used the same cyclic
614) under cyclic or linear conditions. Linear conditions were attained
mmune human IgG1) with or without 2ME were added at indicated
was carried out by addition of an HRP-conjugated polyvalent rabbites 600–
1 (nonipeptide with 2ME, binding decreased significantly but
some activity was still evident because the 2ME does not
c
r
p eptide (
w . An HR
138 VIVEROS ET AL.completely reduce disulfide bonds in the cyclic motif as
was demonstrated on HPLC (data not shown). The fact
that the anti-cyclic sera does not bind to the modified
peptides, when residues at 603 or 609 are alanine sub-
stituted (Fig. 6B), corroborates these data because cys-
teine residues have been removed, which consequently
disallows formation of the cyclic peptide conformation
and results in minimal binding. Additionally, the substi-
tution of the original amino acids by alanine at positions
600, 605, 608, and 613 even increased binding capacity
FIG. 3. Binding of polyclonal rabbit anti sera to two different confor
ollected preimmunization from rabbits immunized with either the line
abbit anti-cyclic and anti-linear peptide sera refer to the sera collected
eptide (IWGCSGKLICTTA). (B) Binding of polyclonal rabbit sera to linear p
ere added at an initial dilution of 1:32, which is the dilution shown hereof anti-cyclic polyclonal sera to these substituted pep-
tides. However, the binding of this serum with peptidestreated with 2ME is evident, although hampered, due to
the fact that all of the peptide is not completely linearized
via chemical reduction methods (Fig. 6B). At the same
time, substitution of any single amino acid had very little
effect on the binding capacity of the polyclonal anti-linear
sera to these peptides. These data demonstrate that the
binding profile of both linear and cyclic polyclonal anti-
sera to GIWGCSGKLICTTAV peptide was quite different
from the binding profile of the CL3 MAb, suggesting that
the neutralizing capability of the CL3 MAb could be
al peptides. Rabbit preimmune anti-linear or anti-cyclic refers to sera
tide (IWGASGKLICTTA) or the cyclic peptide (IWGCSGKLICTTA). The
e third immunization. (A) Binding of polyclonal rabbit antisera to cyclic
IWGASGKLICTTA). All wells were coated with 750 ng of peptide, and sera
P-conjugated goat anti-rabbit IgG was used to detect binding activity.mation
ar pep
after thattributed to the necessity for the LIC residues to be in a
linear conformation.
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139AN HIV-1 NEUTRALIZABLE LINEAR EPITOPE IN gp41Neutralization of HIV-1/MN
To demonstrate the further differences between the
polyclonal sera and the CL3 MAb, we analyzed neutral-
ization of one HIV-1 laboratory isolate by these antibod-
ies. As a positive control, we used a human anti-HIV-1
antibody that has an even higher inhibition potency. Re-
sults demonstrated that based on syncytia quantitation
at 4 days postinfection, neither anti-linear nor anti-cyclic
polyclonal rabbit sera demonstrated HIV-1/MN neutral-
ization. More importantly, the CL3 MAb inhibited cell-free
viral infection of more than 90% (Table 1). These data are
consistent with previous data from our group and outside
collaborators, which demonstrated the ability of the CL3
monoclonal antibody to neutralize infection of chronic T
cell lines and human PBMCs by laboratory-adapted
HIV-1 (Cotropia et al., 1996). In addition, it has been
demonstrated that the CL3 MAb can neutralize infection
of PBMCs by clinical HIV-1 isolates from the B, E, and F
subtypes/clades (Kliks et al., 1994; Ugen, unpublished
ata). Therefore both polyclonal sera had a different
iological activity from CL3 even though they were di-
ected against the same peptide. Using polyclonal rabbit
era, greater than 200 syncytia were recorded in all wells
t every dilution. Infection was monitored daily.
DISCUSSION
The first report of the successful production of a hu-
an MAb that demonstrated binding to, but not neutral-
zation of HIV-1 described the characterization of an
ntibody directed against a region of the HIV-1 gp41
ransmembrane glycoprotein with the sequence
599 609Wain-Hosbon/Gnann
FIG. 4. Binding of rabbit polyclonal antisera to HIV-1 oligomeric and
mmobilized in ELISA plates at 250 ng/well, and binding of antisera atGIWGCSGKLIC (Banapour et al., 1987).
Since then, many human MAbs against both transmem-brane and external proteins of the HIV-1 glycoprotein
envelope have been generated. However, the vast ma-
jority of these antibodies are not able to bind well to any
viral proteins or neutralize infection by HIV-1. Recent
crystallographic data for gp41 and gp120 have demon-
strated that the HIV-1 envelope is a very complex mole-
cule (Kwong et al., 1999; Pinter et al., 1989). The envelope
glycoproteins gp41 and gp120 form oligomeric mole-
cules, most likely trimer structures on the surface of
virions and infected cells (Chan et al., 1997, 1998). These
oligomeric structures are preserved only in clinical (pri-
mary) isolates and not in viruses that have been pas-
saged through different T-cell lines (Moore et al., 1995).
Recently, three human MAbs designated b12, 2G12, and
2F5 were generated that not only bind to the oligomeric
envelope glycoproteins but also neutralize a broad spec-
trum of primary HIV-1 isolates in vitro (Trkola et al., 1995).
These antibodies recognize two epitopes on gp120 (b12,
2G12) and one on gp41 (2F5). The b12 antibodies recog-
nize an epitope overlapping a conserved CD4 binding
site, whereas the 2G12 epitope has been determined to
be within the C2 and C3 regions (near of V3/V4 loops)
of gp120 (Burton, 1997; Wyatt et al., 1998). The MAb
designated 2F5 binds to a very conserved sequence
(ELDKWA) inside the external domain of gp41 (Purtscher
et al., 1994; Conley et al., 1994).
Recently, we described another human MAb against
the immunodominant region (cluster I) of the transmem-
brane glycoprotein of HIV-1 that neutralizes several
TCLA isolates (Cotropia et al., 1996). These data are
different from many other results that have demonstrated
that MAbs against this immunodominant cluster I region
meric envelope proteins. Monomeric gp41 or oligomeric gp160 were
ion of 1:32 is shown.have no neutralizing capacity. It was suggested that
epitopes expressed within this relatively conserved re-
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140 VIVEROS ET AL.gion may not be well expressed on the natural (oligo-
meric) envelope protein of HIV-1 (Sattentau et al., 1995).
hat is why many human MAbs directed against cluster
may not inhibit viral infection. However, our results with
inding of the CL3 MAb to oligomeric glycoproteins (Fig.
) clearly indicates that the specific epitope within the
luster I region is expressed efficiently on HIV-1. There-
ore, we hypothesize that the neutralizing capacity of our
L3 MAb is associated with a unique antigenic epitope
ithin cluster I, rather than with expression of this
pitope on oligomeric, but not monomeric, forms of gp41/
60.
Thus we decided to further analyze the core neutral-
zable epitope recognized by the CL3 monoclonal (GCS-
KLICTT; aa 602–611). To do this, we chemically synthe-
ized a cyclic 15-mer IWGCSGKLICTTAVP (aa residues
00–614) peptide, which includes the original epitope of
L3 (aa residues 602–611). This cyclic peptide became a
ixture of linear and cyclic peptide with the addition of
0 mM 2ME. Both the cyclic and linear/cyclic prepara-
ions were used in ELISA to analyze binding of CL3 to
hese peptides. Surprisingly, the CL3 MAb bound to the
ynthetic peptide only in the presence of 2ME (Fig. 2).
herefore, the CL3 MAb was able to recognize the pep-
ide due to the removal of the disulfide linkage. These
FIG. 5. Binding of CL3 to parent peptide (GIWGCSGKLICTTAV) conta
g of each of the substituted peptides in the presence of 70 mM 2ME. W
he original alanine was substituted with a lysine (K) at residue 612.
oncentration of 100 ng/ml.esults were confirmed with the use of a linear peptide
aving an alanine substitution at residue 603 (C, Cys)
o
f(Fig. 5). Therefore we suggest that the appropriate linear
epitope is not present for CL3 binding when cyclization
occurs. Recent data demonstrated that during binding of
the virus to the corresponding cellular receptors, gp41
undergoes a conformational change, rendering it linear
during formation of a hairpin structure. Accordingly, we
suggest that the epitope on the transmembrane glyco-
protein is exposed to the CL3 MAb when gp41 is in the
linear form during the slow reaction that takes place in
the virus/cell fusion interaction (Chan et al., 1998).
To substantiate these findings, we generated in New
ealand rabbits two polyclonal antisera against both
inear and cyclic peptides and analyzed the binding ca-
acity of these antisera to HIV-1 glycoproteins and pep-
ides from the cluster I region. Interestingly, anti-linear
eptide sera recognized only linear peptide, whereas the
nti-cyclic peptide sera recognized only cyclic peptide
Fig. 3). This demonstrated that the conformations of this
eptide do play a critical role in immunogenicity. Be-
ause the binding capacity of the anti-linear peptide was
imilar to that of the CL3 MAb, we decided to analyze the
eutralizing capacity of this antisera and compare it with
he neutralizing capacity of the CL3 MAb, along with the
nti-cyclic polyclonal sera. It was surprising that neither
nti-cyclic nor anti-linear sera neutralized HIV-1/MN lab-
equential single amino acid substitutions. Wells were coated with 500
e alanine replacement was made is indicated by the amino acid listed.
fers to the original nonmutated parent peptide. CL3 was added at aining s
here thratory isolates, whereas the CL3 MAb inhibited cell-
ree infection very well (Table 1). Thus even though rabbit
o
p
s
i
c
141AN HIV-1 NEUTRALIZABLE LINEAR EPITOPE IN gp41polyclonal antisera recognized the same parent peptide
as the CL3 MAb, neutralization was not realized. We
suggest that antisera specific to the small peptide rec-
ognize several different epitopes but not the one that is
important for viral neutralization. Utilizing a 15-mer pep-
tide containing the ascertained linear epitope and having
a set of sequential single amino acid (alanine) substitu-
tion (original alanine was substituted to lysine) peptides,
we demonstrated that the CL3 MAb binds to the specific
core epitope mapped to three amino acids: L, I, and C
(Fig. 5). However, the binding profile of polyclonal sera to
the same peptides is completely different. Neither poly-
FIG. 6. Binding of rabbit polyclonal anti-linear and anti-cyclic sera to
alanine-substituted peptide set of the parent peptide (GIWGCSGKLICT-
TAV). (A) Binding of rabbit anti-linear sera to amino acid substitutions of
the parent peptide (GIWGCSGKLICTTAV). Rabbit anti-linear sera bind-
ing to the substituted peptide set. The dilution shown is 1:32. Wild type
was not used because the linear form is not natural in vitro. (B) Binding
f rabbit anti-cyclic sera to amino acid substitutions of the parent
eptide (GIWGCSGKLICTTAV). Rabbit anti-cyclic sera binding to the
ubstituted peptide set with the initial dilution of 1:32 shown here. Wild
ndicates the nonmutated parent peptide. Both assays used an HRP-
onjugated anti-rabbit IgG for detection of binding.clonal sera contained antibody directed against the
small epitope mapped to the CL3 MAb. The substitutionof the cysteine residues at 603 and 609 did play a role in
the anti-cyclic binding due to the change in conforma-
tion, but neither sera showed any specificity for residues
607–609 (Fig. 6). Therefore, the CL3 MAb recognizes the
linear core epitope, LIC, which normally does not elicit
an immune response. This is demonstrated with the data
for the polyclonal sera.
These data indicate that within the immunodominant
region of gp41, a linear virus-neutralizing antigenic de-
terminant exists, but it is rarely immunogenic in vivo. This
was established by our inability to produce polyclonal
rabbit sera that recognizes the same neutralizable
epitope of our human MAb. However, based on the
successful development of the CL3 human MAb from an
asymptomatic patient, it is clear that this neutralizable
epitope can be immunogenic in some instances in hu-
mans infected with HIV-1. Further characterization of the
ability of the CL3 human MAb to neutralize in vitro infec-
tion of PBMCs by clinical HIV-1 isolates is being pur-
sued.
MATERIALS AND METHODS
Generation, characterization, and purification of the
CL3 human MAb
The following briefly describes the generation of the
CL3 human MAb. An asymptomatic individual infected
with HIV-1 who had high titers of neutralizing plasma
antibodies against HIV-1 was selected as a donor of
peripheral B-lymphocytes that were subsequently trans-
formed by the Epstein–Barr virus. Using ELISA method-
ology, the supernatants from culture wells containing
lymphoblastoid cells were assayed for antibodies to
HIV-1 using whole viral lysates and HIV-1 envelope gly-
coproteins. These cells did not produce antibodies
against nonspecific antigens. To stabilize antibody pro-
duction, the lymphoblastoid cell lines were fused with
heteromyelomas to generate hybridomas and were sub-
sequently subjected to limiting dilution to develop indi-
vidual clones.
CL3, among other human monoclonal antibodies, was
generated by this technique (Cotropia et al., 1996). It is
TABLE 1
Effect of Rabbit Antipeptide Antisera and Clore 3 Human Monoclonal
Antibody on Infection of MT-2 Cells by Cell Free HIV-1 MN
Antibody
Mean syncytia
quantificationa
Rabbit a-linear sera (1:64 dilution) .200
Rabbit a-cyclic sera (1:64 dilution) .200
CL3 human immunoglobulin (10 mg/ml) ,20
Normal human immunoglobulin (10 mg/ml) .200
Human anti-HIV immunoglobulin (3.125 mg/ml) 0a Based on day 4 counts at 103 magnification.
f
n
s
s
I
6
c
d
1
m
t
f
n
t
p
f
d
u
m
p
t
s
i
a
a
o
a
o
H
u
m
l
F
q
p
a
v
b
v
w
w
B
g
c
e
g
m
f
1
t
o
d
142 VIVEROS ET AL.important to mention that the CL3 MAb was specific for
the gp41 envelope glycoprotein of HIV-1. This MAb reacts
to gp41 in lysates of both cell-free HIV-1 and HIV-1-
infected cells as well as lysates of BSC-1 infected with
recombinant vaccinia virus, which expresses the gp41
envelope glycoprotein (Cotropia, 1996; Ugen, unpub-
lished data).
The CL3 MAb was purified from hybridoma cell culture
supernatant as we previously described (Cotropia et al.,
1996). Briefly, aliquots of hybridoma cell culture superna-
tants were subjected to batch immunoadsorption utiliz-
ing Sepharose Protein-G (Pharmacia, Piscataway, NJ).
The immunoadsorbed MAb was eluted using low pH
buffer (0.16 M glycine-HCl, pH 2.4) with rapid neutraliza-
tion of eluate. The IgG1 subclass quantification was per-
ormed on affinity-purified immunoglobulin in a two-site
oncompetitive immunoenzymetric assay (IEMA) as de-
cribed (Cotropia et al., 1996). Routinely, from 10 liters of
upernatant, we isolated 300–350 mg of human IgG1 with
a typical concentration of 30–35 mg/ml. Recently, we
increased production of CL3 6–7 times in vitro by using
Ultra Low IgG fetal bovine serum (GIBCO, Rockville, MD)
rather than characterized fetal bovine serum (Hyclone
Laboratories, Inc., Logan, UT), which was used previ-
ously.
Synthesis of peptides
Both a linear peptide and a cyclic peptide with the
sequences of H2N-IWGASGKLICTTAVP-COOH and H2N-
WGCSGKLICTTAVP-COOH, respectively (residues 600–
14 according to Wain-Hobson/Gnann alignment), were
hemically synthesized by Merrifield’s stepwise proce-
ure (Burton, 1997) with some modifications (Merrifield,
963). All coupling reactions to form peptide bonds were
ediated by N,N9-dicyclohexylcarbodiimide. In general,
wo coupling steps were used for each amino acid,
ollowed by acetic anhydride capping of any remaining
onreactive amine. To obtain the monomeric cyclic pep-
ide, we took advantage of a solid-phase pseudodilution
henomenon, which favors intramolecular disulfide bond
ormation (Garcia-Echeverria et al., 1989), carrying out
eprotection and oxidation of the cysteines by iodine
nder acidic conditions while the peptide chain re-
ained anchored to the resin. Removal of all side-chain
rotecting groups and simultaneous cleavage of the pep-
ide from the resin was performed with trifluoromethane-
ulfonic acid (Tam et al., 1986). The crude peptide was
nitially purified on a column with Sephadex G-15 in 0.1 M
mmonium bicarbonate and then by chromatography on
column of carboxymethyl cellulose in a linear gradient
f ammonium acetate (0.01–1 M) at a constant pH 4.5,
nd the peptide was then lyophilized. The homogeneity
f the peptide was confirmed by analytical reverse phase
PLC on a Waters (Milford, MA) model 600E instrument
sing a Delta Pak C18 column (3.9 3 150 mm). Auto-ated sequence analysis of the peptide on a pulse
iquid-phase protein sequencer (Applied Biosystems,
oster City, CA) confirmed the correct amino acid se-
uence of the peptide.
For fine epitope mapping of the CL3 MAb, a set of 16
eptides (amino acid residues 599–613) was synthesized
s described earlier (Goudsmit et al., 1990). The peptides
have a sequential single amino acid (alanine) substitu-
tion (the original alanine was substituted with lysine).
The original peptide, GIWGCSGKLICTTAV, as well as the
set of substituted peptides, was used in ELISA to mea-
sure its specificity for the CL3 MAb and polyclonal sera.
Preparation of polyclonal rabbit sera
Rabbits were maintained in accordance with the
guidelines of the Committee on Animals for the Instituto
de Investigaciones Biomedicas and the “Guide for the
Care and Use of Laboratory Animals” (Institute of labo-
ratory Animal Resources, Commission on Life Sciences,
National Research Council, National Academy Press,
Washington, D.C.). All procedures with rabbits were per-
formed using a special box to restrict any abrupt move-
ments of the animals. Two New Zealand White female
rabbits were immunized with the synthetic linear peptide,
while two others were administered the cyclic peptide.
Subcutaneous injections (s.c.) consisted of 500 mg of
carrier-free peptide in 500 ml of saline solution mixed
with 500 ml of complete Freund’s adjuvant for the first
injection and then 500 ml of incomplete Freund’s adju-
ant for each of the subsequent booster injections. Rab-
it blood was collected at 2-week intervals, using the ear
ein after the third and forth injections. The samples
ere then centrifuged at 3200 rpm for 10 min, and sera
as removed and stored at 220°C.
inding of CL3 and polyclonal sera to oligomeric
p160 and synthetic peptides
The first step in the characterization of MAb and poly-
lonal antisera was to determine its binding to HIV-1
nvelope glycoproteins. The binding of CL3 to oligomeric
p160/LAV (Protein Sciences Corp., Meriden, CT) and
onomeric gp160/IIIB (Immunodiagnostics, Inc., Bed-
ord, MA) was determined by ELISA (Cotropia et al.,
996). Briefly, Immulon 4HBX microplates (Dynex, Chan-
illy, VA) were coated with 100 ng/well either oligomeric
r monomeric gp160. Plates were blocked with 5% nonfat
ry milk in PBS. Purified CL3 MAb and human IgG1 were
added to the wells at the different concentrations.
Anti-human polyvalent Ig conjugated with horseradish
peroxidase (Sigma Chemical Co., St. Louis, MO) was
added at a 1:20,000 dilution and then developed with
3,3,5,5-tetramethylbenzidine tablets (Sigma) in perborate
buffer. Plates were then read spectrophotometrically at
450 nm.
In the case of the rabbit serum, plates were coated
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143AN HIV-1 NEUTRALIZABLE LINEAR EPITOPE IN gp41with monomeric gp41 (Immunodiagnostics Inc., Bedford,
MA) or oligomeric gp160 (Protein Sciences Corp.) enve-
lope glycoproteins. Then both the anti-linear and anti-
cyclic rabbit sera were added. Peroxidase-conjugated
goat anti-rabbit IgG (Zymed, San Francisco, CA) was
used for antibody detection. As we indicated, the CL3
MAb was specific for gp41 but not for gp120 or other viral
or nonviral antigens. Importantly, both polyclonal anti-
sera also bound in ELISA to gp41 but not to gp120 (data
not shown). Finally, as demonstrated by FACS analysis,
both CL3 MAb (Cotropia et al., 1996) and polyclonal
anti-peptide antisera (data not shown) bound to SUPT1
T-cells only after infection of this target cell line with the
HIV-1/3B isolate.
The binding of the CL3 MAb and both rabbit polyclonal
sera to the synthetic peptides was determined as fol-
lows: wells were coated with 750 ng of indicated peptide
in carbonate/bicarbonate buffer, with or without 70 mM
2ME (Fisher Scientific, Pittsburgh, PA). CL3 was added at
an initial concentration of 140 ng/ml and diluted twofold
to a final concentration of 1.09 ng/ml. Antisera were
added to the wells in different dilution starting with 1:32.
Horseradish peroxidase-conjugated anti-human or anti-
rabbit secondary antibodies were used for detection of
binding.
For the fine epitope mapping of the CL3 MAb, we
analyzed the binding of the antibody, as well as the
polyclonal rabbit sera, to the set of 15-mer peptides
described above by ELISA. This assay was performed
using the same protocol as above except that plates
were coated with 500 ng/well of the selected peptide.
Neutralization assay of HIV-1/MN by polyclonal
rabbit sera
Neutralization assays with CL3 were performed by
modification of procedures previously described (Co-
tropia et al., 1996). In these assays, nonimmune human
gG1 (Sigma) was used as a negative control for neutral-
ization, and pooled HIV Ig, obtained from the AIDS Re-
search and Reference Reagent Program, was used as a
positive neutralization control.
We also analyzed neutralization of HIV-1MN cell-free
virus by polyclonal anti-peptide sera. Both anti-linear and
anti-cyclic rabbit polyclonal sera were initially diluted to
1:64 and then diluted serially twofold up to 1:1024. All
samples were run in duplicate with normal rabbit serum
(Sigma) as the negative control. Fifty microliters of both
the samples (different dilutions) and the 100 TCID50 of
irus were mixed and incubated for 2 h at 37°C. As target
ells, we used MT-2 cells (HTLV-1 infected), which were
dded to the wells at a concentration of 2000 cells/well
nd incubated overnight at 37°C.
The next day, the plates were washed twice by spin-
ing the plates and replacing the supernatant with fresh
PMI 1640 (Mediatech, Inc., Herndon, VA) complete me-ium. Quantification of syncytia was performed on day 4
sing inverted light microscopy at 403 magnification.
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